These two British drugs behemoths are similar businesses that both pay big dividends, and they’ve mostly tended to move in lockstep. However, in recent months GlaxoSmithKline (LSE: GSK) has sported a much higher — and hence more potentially more attractive — yield than AstraZeneca (LSE: AZN). So what’s up? Owain Bennallack investigates…